Inversago Pharma
Michèle Desjardins has over 20 years of work experience in the pharmaceutical industry. Michèle began their career in 1999 at Pharmetics Inc. as a Laboratory Technician/QA Technician. In 2001, they joined Galderma as a QA Supervisor, Quality Assurance Auditor and Laboratory Analyst. In 2014, they were promoted to Senior QA Specialist- Contract Manufacturing and QA Specialist Contract Manufacturing. In 2017, they moved to Clementia Pharmaceuticals Inc. as an Associate Director Quality Assurance and Senior Manager, Quality Assurance. In 2020, they joined Ipsen as Director Global Quality & Compliance and Montreal Site Head and Director Quality Assurance - Global Quality. Currently, they are a Senior Director Quality Assurance at Inversago Pharma.
Michèle Desjardins obtained a DESS in Pharmacy from Université de Montréal between 2002 and 2004, and a BSc in Chemistry from Université du Québec à Montréal between 1996 and 1999.
This person is not in any offices
Inversago Pharma
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).